Retrospective Chart Review to Evaluate Safety and Tolerability of ADVATE Among Previously Untreated Patients in China With Moderate to Severe Hemophilia A
Phase of Trial: Phase IV
Latest Information Update: 20 Oct 2017
At a glance
- Drugs Rurioctocog alfa (Primary)
- Indications Haemophilia A
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Baxalta
- 10 Jun 2017 Biomarkers information updated
- 22 Jun 2016 Status changed from recruiting to completed.
- 22 Feb 2016 Status changed from not yet recruiting to recruiting as per ClinicalTrials.gov record.